The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform
D L Sparks - One of the best experts on this subject based on the ideXlab platform.
-
peripheral ethanolamine plasmalogen deficiency a logical Causative Factor in alzheimer s disease and dementia
Journal of Lipid Research, 2007Co-Authors: Dayan B Goodenowe, Lisa Cook, Yingshen Lu, Dushmanthi Jayasinghe, Pearson W K Ahiahonu, Doug Heath, Yasuyo Yamazaki, John Flax, Kevin Krenitsky, D L SparksAbstract:Although dementia of the Alzheimer's type (DAT) is the most common form of dementia, the severity of de- mentia is only weakly correlated with DAT pathology. In con- trast, postmortem measurements of cholinergic function and membrane ethanolamine plasmalogen (PlsEtn) content in the cortex and hippocampus correlate with the severity of dementia in DAT. Currently, the largest risk Factor for DAT is age. Because the synthesis of PlsEtn occurs via a single nonredundant peroxisomal pathway that has been shown to decrease with age and PlsEtn is decreased in the DAT brain, we investigated potential relationships between serum PlsEtn levels, dementia severity, and DAT pathology. In total, serum PlsEtn levels were measured in five inde- pendent population collections comprising .400 clinically demented and .350 nondemented subjects. Circulating PlsEtn levels were observed to be significantly decreased in serum from clinically and pathologically diagnosed DAT subjects at all stages of dementia, and the severity of this decrease correlated with the severity of dementia. Further- more, a linear regression model predicted that serum PlsEtn levels decrease years before clinical symptoms. The puta- tive roles that PlsEtn biochemistry play in the etiology of cholinergicdegeneration,amyloidaccumulation,anddemen- tia are discussed.—Goodenowe, D. B., L. L. Cook, J. Liu, Y. Lu, D. A. Jayasinghe, P. W. K. Ahiahonu, D. Heath, Y. Yamazaki, J. Flax, K. F. Krenitsky, D. L. Sparks, A. Lerner, R. P. Friedland, T. Kudo, K. Kamino, T. Morihara, M. Takeda, and P. L. Wood. Peripheral ethanolamine plasma- logen deficiency: a logical Causative Factor in Alzheimer's disease and dementia. J. Lipid Res. 2007. 48: 2485-2498.
-
peripheral ethanolamine plasmalogen deficiency a logical Causative Factor in alzheimer s disease and dementia
Journal of Lipid Research, 2007Co-Authors: Dayan B Goodenowe, Lisa Cook, Dushmanthi Jayasinghe, Pearson W K Ahiahonu, Doug Heath, Yasuyo Yamazaki, John Flax, Kevin Krenitsky, Jun Liu, D L SparksAbstract:Although dementia of the Alzheimer's type (DAT) is the most common form of dementia, the severity of dementia is only weakly correlated with DAT pathology. In contrast, postmortem measurements of cholinergic function and membrane ethanolamine plasmalogen (PlsEtn) content in the cortex and hippocampus correlate with the severity of dementia in DAT. Currently, the largest risk Factor for DAT is age. Because the synthesis of PlsEtn occurs via a single nonredundant peroxisomal pathway that has been shown to decrease with age and PlsEtn is decreased in the DAT brain, we investigated potential relationships between serum PlsEtn levels, dementia severity, and DAT pathology. In total, serum PlsEtn levels were measured in five independent population collections comprising >400 clinically demented and >350 nondemented subjects. Circulating PlsEtn levels were observed to be significantly decreased in serum from clinically and pathologically diagnosed DAT subjects at all stages of dementia, and the severity of this decrease correlated with the severity of dementia. Furthermore, a linear regression model predicted that serum PlsEtn levels decrease years before clinical symptoms. The putative roles that PlsEtn biochemistry play in the etiology of cholinergic degeneration, amyloid accumulation, and dementia are discussed.
Mehmet Ali Sungur - One of the best experts on this subject based on the ideXlab platform.
-
behcet s disease as a Causative Factor of cerebral venous sinus thrombosis subgroup analysis of data from the venost study
Rheumatology, 2019Co-Authors: Derya Uluduz, Ipek Midi, Taskin Duman, Sena Colakoglu, Ahmet Tufekci, Mustafa Bakar, Bijen Nazliel, Nida Tascilar, Baki Goksan, Mehmet Ali SungurAbstract:OBJECTIVE This study was performed to determine the rate of cerebral venous sinus thrombosis (CVST) among cases of Behcet's disease (BD) included in a multicentre study of cerebral venous sinus thrombosis (VENOST). METHODS VENOST was a retrospective and prospective national multicentre observational study that included 1144 patients with CVST. The patients were classified according to aetiologic Factors, time of CVST symptom onset, sinus involvement, treatment approach and prognosis. RESULTS BD was shown to be a Causative Factor of CVST in 108 (9.4%) of 1144 patients. The mean age of patients in the BD group was 35.27 years and 68.5% were men, whereas in the non-BD CVST group, the mean age was 40.57 years and 28.3% were men (P < 0.001). Among the aetiologic Factors for patients aged 18-36 years, BD was predominant for men, and puerperium was predominant for women. The onset of symptoms in the BD group was consistent with the subacute form. The transverse sinuses were the most common sites of thrombosis, followed by the superior sagittal sinuses. The most common symptom was headache (96.2%), followed by visual field defects (38%). CONCLUSIONS BD was found in 9.4% of patients in our VENOST series. Patients with BD were younger and showed a male predominance. The functional outcome of CVST in patients with BD was good; only 12% of patients presenting with cranial nerve involvement and altered consciousness at the beginning had a poor outcome (modified Rankin Score ⩾2).
Dayan B Goodenowe - One of the best experts on this subject based on the ideXlab platform.
-
peripheral ethanolamine plasmalogen deficiency a logical Causative Factor in alzheimer s disease and dementia
Journal of Lipid Research, 2007Co-Authors: Dayan B Goodenowe, Lisa Cook, Yingshen Lu, Dushmanthi Jayasinghe, Pearson W K Ahiahonu, Doug Heath, Yasuyo Yamazaki, John Flax, Kevin Krenitsky, D L SparksAbstract:Although dementia of the Alzheimer's type (DAT) is the most common form of dementia, the severity of de- mentia is only weakly correlated with DAT pathology. In con- trast, postmortem measurements of cholinergic function and membrane ethanolamine plasmalogen (PlsEtn) content in the cortex and hippocampus correlate with the severity of dementia in DAT. Currently, the largest risk Factor for DAT is age. Because the synthesis of PlsEtn occurs via a single nonredundant peroxisomal pathway that has been shown to decrease with age and PlsEtn is decreased in the DAT brain, we investigated potential relationships between serum PlsEtn levels, dementia severity, and DAT pathology. In total, serum PlsEtn levels were measured in five inde- pendent population collections comprising .400 clinically demented and .350 nondemented subjects. Circulating PlsEtn levels were observed to be significantly decreased in serum from clinically and pathologically diagnosed DAT subjects at all stages of dementia, and the severity of this decrease correlated with the severity of dementia. Further- more, a linear regression model predicted that serum PlsEtn levels decrease years before clinical symptoms. The puta- tive roles that PlsEtn biochemistry play in the etiology of cholinergicdegeneration,amyloidaccumulation,anddemen- tia are discussed.—Goodenowe, D. B., L. L. Cook, J. Liu, Y. Lu, D. A. Jayasinghe, P. W. K. Ahiahonu, D. Heath, Y. Yamazaki, J. Flax, K. F. Krenitsky, D. L. Sparks, A. Lerner, R. P. Friedland, T. Kudo, K. Kamino, T. Morihara, M. Takeda, and P. L. Wood. Peripheral ethanolamine plasma- logen deficiency: a logical Causative Factor in Alzheimer's disease and dementia. J. Lipid Res. 2007. 48: 2485-2498.
-
peripheral ethanolamine plasmalogen deficiency a logical Causative Factor in alzheimer s disease and dementia
Journal of Lipid Research, 2007Co-Authors: Dayan B Goodenowe, Lisa Cook, Dushmanthi Jayasinghe, Pearson W K Ahiahonu, Doug Heath, Yasuyo Yamazaki, John Flax, Kevin Krenitsky, Jun Liu, D L SparksAbstract:Although dementia of the Alzheimer's type (DAT) is the most common form of dementia, the severity of dementia is only weakly correlated with DAT pathology. In contrast, postmortem measurements of cholinergic function and membrane ethanolamine plasmalogen (PlsEtn) content in the cortex and hippocampus correlate with the severity of dementia in DAT. Currently, the largest risk Factor for DAT is age. Because the synthesis of PlsEtn occurs via a single nonredundant peroxisomal pathway that has been shown to decrease with age and PlsEtn is decreased in the DAT brain, we investigated potential relationships between serum PlsEtn levels, dementia severity, and DAT pathology. In total, serum PlsEtn levels were measured in five independent population collections comprising >400 clinically demented and >350 nondemented subjects. Circulating PlsEtn levels were observed to be significantly decreased in serum from clinically and pathologically diagnosed DAT subjects at all stages of dementia, and the severity of this decrease correlated with the severity of dementia. Furthermore, a linear regression model predicted that serum PlsEtn levels decrease years before clinical symptoms. The putative roles that PlsEtn biochemistry play in the etiology of cholinergic degeneration, amyloid accumulation, and dementia are discussed.
Derya Uluduz - One of the best experts on this subject based on the ideXlab platform.
-
behcet s disease as a Causative Factor of cerebral venous sinus thrombosis subgroup analysis of data from the venost study
Rheumatology, 2019Co-Authors: Derya Uluduz, Ipek Midi, Taskin Duman, Sena Colakoglu, Ahmet Tufekci, Mustafa Bakar, Bijen Nazliel, Nida Tascilar, Baki Goksan, Mehmet Ali SungurAbstract:OBJECTIVE This study was performed to determine the rate of cerebral venous sinus thrombosis (CVST) among cases of Behcet's disease (BD) included in a multicentre study of cerebral venous sinus thrombosis (VENOST). METHODS VENOST was a retrospective and prospective national multicentre observational study that included 1144 patients with CVST. The patients were classified according to aetiologic Factors, time of CVST symptom onset, sinus involvement, treatment approach and prognosis. RESULTS BD was shown to be a Causative Factor of CVST in 108 (9.4%) of 1144 patients. The mean age of patients in the BD group was 35.27 years and 68.5% were men, whereas in the non-BD CVST group, the mean age was 40.57 years and 28.3% were men (P < 0.001). Among the aetiologic Factors for patients aged 18-36 years, BD was predominant for men, and puerperium was predominant for women. The onset of symptoms in the BD group was consistent with the subacute form. The transverse sinuses were the most common sites of thrombosis, followed by the superior sagittal sinuses. The most common symptom was headache (96.2%), followed by visual field defects (38%). CONCLUSIONS BD was found in 9.4% of patients in our VENOST series. Patients with BD were younger and showed a male predominance. The functional outcome of CVST in patients with BD was good; only 12% of patients presenting with cranial nerve involvement and altered consciousness at the beginning had a poor outcome (modified Rankin Score ⩾2).
Pearson W K Ahiahonu - One of the best experts on this subject based on the ideXlab platform.
-
peripheral ethanolamine plasmalogen deficiency a logical Causative Factor in alzheimer s disease and dementia
Journal of Lipid Research, 2007Co-Authors: Dayan B Goodenowe, Lisa Cook, Yingshen Lu, Dushmanthi Jayasinghe, Pearson W K Ahiahonu, Doug Heath, Yasuyo Yamazaki, John Flax, Kevin Krenitsky, D L SparksAbstract:Although dementia of the Alzheimer's type (DAT) is the most common form of dementia, the severity of de- mentia is only weakly correlated with DAT pathology. In con- trast, postmortem measurements of cholinergic function and membrane ethanolamine plasmalogen (PlsEtn) content in the cortex and hippocampus correlate with the severity of dementia in DAT. Currently, the largest risk Factor for DAT is age. Because the synthesis of PlsEtn occurs via a single nonredundant peroxisomal pathway that has been shown to decrease with age and PlsEtn is decreased in the DAT brain, we investigated potential relationships between serum PlsEtn levels, dementia severity, and DAT pathology. In total, serum PlsEtn levels were measured in five inde- pendent population collections comprising .400 clinically demented and .350 nondemented subjects. Circulating PlsEtn levels were observed to be significantly decreased in serum from clinically and pathologically diagnosed DAT subjects at all stages of dementia, and the severity of this decrease correlated with the severity of dementia. Further- more, a linear regression model predicted that serum PlsEtn levels decrease years before clinical symptoms. The puta- tive roles that PlsEtn biochemistry play in the etiology of cholinergicdegeneration,amyloidaccumulation,anddemen- tia are discussed.—Goodenowe, D. B., L. L. Cook, J. Liu, Y. Lu, D. A. Jayasinghe, P. W. K. Ahiahonu, D. Heath, Y. Yamazaki, J. Flax, K. F. Krenitsky, D. L. Sparks, A. Lerner, R. P. Friedland, T. Kudo, K. Kamino, T. Morihara, M. Takeda, and P. L. Wood. Peripheral ethanolamine plasma- logen deficiency: a logical Causative Factor in Alzheimer's disease and dementia. J. Lipid Res. 2007. 48: 2485-2498.
-
peripheral ethanolamine plasmalogen deficiency a logical Causative Factor in alzheimer s disease and dementia
Journal of Lipid Research, 2007Co-Authors: Dayan B Goodenowe, Lisa Cook, Dushmanthi Jayasinghe, Pearson W K Ahiahonu, Doug Heath, Yasuyo Yamazaki, John Flax, Kevin Krenitsky, Jun Liu, D L SparksAbstract:Although dementia of the Alzheimer's type (DAT) is the most common form of dementia, the severity of dementia is only weakly correlated with DAT pathology. In contrast, postmortem measurements of cholinergic function and membrane ethanolamine plasmalogen (PlsEtn) content in the cortex and hippocampus correlate with the severity of dementia in DAT. Currently, the largest risk Factor for DAT is age. Because the synthesis of PlsEtn occurs via a single nonredundant peroxisomal pathway that has been shown to decrease with age and PlsEtn is decreased in the DAT brain, we investigated potential relationships between serum PlsEtn levels, dementia severity, and DAT pathology. In total, serum PlsEtn levels were measured in five independent population collections comprising >400 clinically demented and >350 nondemented subjects. Circulating PlsEtn levels were observed to be significantly decreased in serum from clinically and pathologically diagnosed DAT subjects at all stages of dementia, and the severity of this decrease correlated with the severity of dementia. Furthermore, a linear regression model predicted that serum PlsEtn levels decrease years before clinical symptoms. The putative roles that PlsEtn biochemistry play in the etiology of cholinergic degeneration, amyloid accumulation, and dementia are discussed.
